VSTM Company Profile and Key Details
Verastem
Price Chart
Stock Price Today
Verastem, Inc. (VSTM) stock declined over -2.58%, trading at $4.15 on NASDAQ, down from the previous close of $4.26. The stock opened at $4.29, fluctuating between $4.11 and $4.37 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 19, 2026 | 4.25 | 4.37 | 4.11 | 4.15 | 1.73M |
| May 18, 2026 | 4.31 | 4.37 | 4.23 | 4.26 | 1.66M |
| May 15, 2026 | 4.70 | 4.75 | 4.30 | 4.32 | 2.2M |
| May 14, 2026 | 4.71 | 4.95 | 4.68 | 4.71 | 1.74M |
| May 13, 2026 | 4.60 | 4.79 | 4.49 | 4.72 | 1.91M |
| May 12, 2026 | 4.93 | 5.00 | 4.62 | 4.63 | 2.27M |
| May 11, 2026 | 4.89 | 5.29 | 4.86 | 4.88 | 3.07M |
| May 08, 2026 | 5.45 | 5.54 | 4.75 | 4.89 | 7.55M |
| May 07, 2026 | 5.98 | 6.05 | 5.63 | 5.66 | 2.75M |
| May 06, 2026 | 5.93 | 6.10 | 5.90 | 6.01 | 1.89M |
| May 05, 2026 | 6.00 | 6.08 | 5.83 | 5.96 | 1.2M |
| May 04, 2026 | 5.82 | 6.04 | 5.82 | 5.95 | 1.8M |
| Apr 30, 2026 | 5.49 | 5.56 | 5.38 | 5.46 | 1.58M |
| Apr 29, 2026 | 5.46 | 5.46 | 5.19 | 5.40 | 2.84M |
| Apr 28, 2026 | 5.53 | 5.73 | 5.37 | 5.46 | 1.92M |
| Apr 27, 2026 | 5.83 | 6.04 | 5.53 | 5.54 | 1.37M |
| Apr 23, 2026 | 6.09 | 6.27 | 6.01 | 6.23 | 2.41M |
| Apr 22, 2026 | 6.09 | 6.49 | 6.05 | 6.07 | 1.59M |
| Apr 21, 2026 | 6.53 | 6.53 | 5.91 | 6.05 | 1.72M |
| Apr 20, 2026 | 6.60 | 6.65 | 6.24 | 6.52 | 1.93M |
Contact Details
About Company
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Company Information
| Employees | 78 |
| Beta | 0.4 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Senior Vice President, Gen. Counsel & Sec.
Mr. Richard H. Aldrich M.B.A., Mba
Founder and Consultant
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Daniel Calkins
Head of Investor Relations, Vice President of Fin. and Principal Accounting Officer & Financial Officer
Dr. Piyush B. Gupta Ph.D.
Co-Founder
Ms. Erin S. Cox
Senior Director of Investor Relations & Corporation Communications
Dr. Michelle Dipp M.D., Ph.D.
Co-Founder
Mr. Daniel W. Paterson
Pres, Chief Executive Officer & Director
Ms. Lisa Buffington
Senior Vice President of Corporation Communications & Patient Advocacy
Mr. Brian M. Stuglik BPHARM, R.Ph., RPh
Chief Executive Officer & Director
Lisa Buffington
Head of Corporation Communications
Mr. Ajay Munshi
Vice President of Corporation Devel.
Mr. Brian M. Stuglik BPHARM, RPh
Chief Executive Officer & Director
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep